Beyond the ETF: Five Niches Where Biotech Beats the S&P 500

Why biotech ETFs underperform — and where the real edge lives

Prepared by richstorm.co

Key Takeaways

▸  Biotech ETFs underperform the S&P 500 because they capture the mediocre average, not the exceptional individual outcomes.

▸  The five niches — catalyst trading, pre-acquisition, post-approval ramp, therapeutic area wave, and platform discounts — each offer returns that don't exist in passive investing.

▸  Pre-acquisition positioning is the most accessible niche: big pharma's patent cliff forces predictable M&A that pays 60–120% premiums on announcement day.

▸  For most retail investors, the best starting point is a basket of stocks in a therapeutic area with converging big pharma M&A interest — no science required.

▸  Selective biotech works best as a satellite alongside a passive S&P 500 core — two complementary strategies driven by fundamentally different return mechanisms.

THE PARADOX — ETFS UNDERPERFORM, YET THE EDGE EXISTS

Our analysis across this research series has reached a conclusion that initially appears contradictory: biotech ETFs — the most accessible way for retail investors to gain biotech exposure — have underperformed the S&P 500 over both 5-year and 10-year periods, with far greater volatility. Yet sophisticated investors continue to allocate meaningfully to the sector and, in some cases, generate returns that dwarf those available in passive index investing.

This is not a contradiction. It reflects a fundamental truth about how biotech returns are distributed. The sector's average return, captured by ETFs, is mediocre. But the distribution of individual outcomes within the sector is extraordinarily wide — from total losses on failed clinical trials to 10-20x returns on correctly identified acquisition targets or breakthrough approvals. ETFs, by owning everything, capture the average. Selective investors who understand the sector's specific return mechanics can target the right tail of that distribution.

The S&P 500 is a bet on corporate earnings growing over time across a diversified economy. Biotech is a bet on specific, scheduled, researchable events resolving in your favour. Those are fundamentally different bets — and the second one only beats the first when you have genuine analytical edge at the moment of each event.

The performance record, plainly stated

The data from our ETF analysis is unambiguous on this point:

* ARKG launched October 2014; figure reflects since-inception CAGR through April 2026.

Why the ETF wrapper destroys the biotech edge

The S&P 500 outperforming biotech ETFs is not evidence that there is no biotech alpha — it is evidence that the ETF vehicle is the wrong tool for accessing it. Four structural reasons explain why:

• Indiscriminate ownership: An ETF buys every company in its index or universe, regardless of pipeline quality, financial health, or M&A attractiveness. It owns the 20 companies most likely to fail their Phase 3 trials with exactly the same enthusiasm as the 5 companies most likely to be acquired at 100% premiums.

• No event selectivity: The entire biotech alpha thesis rests on specific, timed events: Phase 3 readouts, FDA decisions, licensing deals, acquisition announcements. An ETF holds through every event on every company whether or not any analytical edge exists on that event.

• Dilution of M&A premiums: When XBI (equal-weight) holds 145 companies and one is acquired at a 100% premium, that event contributes approximately 0.7% to the fund's return. A concentrated investor who owned that company at 5% of their portfolio gains 5%. The ETF captures the event; the selective investor captures the magnitude.

• Bear market amplification: Biotech ETFs are disproportionately exposed to the sector's cyclicality. When rising rates or risk-off sentiment hits pre-revenue companies, every name in the ETF suffers simultaneously. A selective investor holding only late-stage or post-approval companies avoids the worst of these drawdowns.

THE FIVE NICHES — WHERE BIOTECH ALPHA IS ACTUALLY GENERATED

The following five niches represent the specific contexts in which a selective biotech investor can generate returns that are structurally unavailable in the S&P 500. Each niche has a distinct return mechanism, a specific required skill set, and a frank difficulty rating. They are presented in order of increasing required expertise — retail investors without scientific backgrounds should focus on niches 2, 3, and 4 before attempting 1 or 5.

NICHE 1  Catalyst event trading

Buy before a binary data readout when you have edge on the probability — sell into the move

Difficulty: ●●●●○  4 / 5 

The return mechanism

The S&P 500 has no equivalent of a single binary event that moves a stock 50-150% in a single session. A clinical trial readout — Phase 2 or Phase 3 data release — is a pre-announced, calendared event that any investor can research in advance. When your probability estimate for a successful outcome is meaningfully higher than what the market is currently pricing into the stock, buying ahead of the readout and selling into the subsequent move generates returns that simply do not exist in large-cap equity markets.

What makes this different from gambling

The distinction between informed catalyst trading and speculation is the quality of the pre-event thesis. A gambler buys before a readout because they hope for good news. An informed investor buys because they have identified a specific reason why the probability of success is higher than the market believes — for example: the Phase 2 effect size was stronger than the consensus read, the trial endpoint is more achievable than analysts modelled, or the patient population was selected in a way that increases the likelihood of hitting the primary endpoint. Without a specific, articulable edge, this niche should not be attempted.

Required skills

• Protocol reading: ClinicalTrials.gov provides full trial protocols including primary endpoints, patient selection criteria, and statistical powering assumptions. The key question is not 'does this drug work' but 'is this trial designed in a way that makes the primary endpoint achievable given what Phase 2 told us?'

• Endpoint fluency: Understanding the difference between a surrogate endpoint and a clinical outcome endpoint, and which FDA divisions accept each, is essential. Many trials fail not because the drug does not work but because the chosen endpoint does not satisfy regulators.

• Historical analogue analysis: What happened to similar drugs in similar patient populations with similar endpoint designs? Analysing historical success rates in a specific indication provides a baseline probability that the market may not have correctly calibrated.

Real examples — 2023 to 2025

Why this beats the S&P 500: A 100% return in a single day from a pre-researched, scheduled event is structurally unavailable in large-cap equity markets. No earnings release, no product launch, no analyst upgrade produces this magnitude of return from a researchable catalyst. The edge is in the probability gap between your assessment and the market's.

NICHE 2  Pre-acquisition positioning

Identify who big pharma will buy before announcement — collect the 60–120% premium

Difficulty: ●●●○○  3 / 5 

The return mechanism

Big pharma's $300 billion patent cliff exposure by 2030 creates a structural, non-cyclical acquisition imperative. The companies being acquired are small and mid-cap biotechs whose drugs fill the specific revenue gaps that big pharma will lose when their blockbusters go off-patent. Acquisition premiums in 2025 averaged 60-120% over the pre-announcement stock price. An investor who correctly positions in a target company before the deal is announced receives the full premium on announcement day — a return that is structurally unavailable in any other segment of public equity markets.

Required skills — this niche is accessible to non-scientists

Unlike clinical trial trading, pre-acquisition positioning requires business analysis rather than scientific expertise. The core skill is cross-referencing big pharma strategic priorities against the small/mid-cap universe:

• Read acquirer earnings calls: Big pharma CEOs explicitly name the therapeutic areas they are prioritising for M&A, often months before any deal. J&J explicitly named CNS/neurology as a top acquisition priority in 2024 earnings calls — and subsequently paid $14.6 billion for Intra-Cellular Therapies in 2025.

• Map patent cliff exposure: Each major pharma company's investor relations materials disclose upcoming loss-of-exclusivity (LOE) events. A drug generating $5B annually that goes off-patent in 2028 creates a specific, quantifiable acquisition need. The acquirer for a COPD drug will be a company losing a COPD blockbuster.

• Spot pre-acquisition signals: Licensing deals, research collaborations, and equity stakes by big pharma frequently precede full acquisitions. A licensing agreement for ex-US rights is often a low-commitment due diligence mechanism before committing to a full global acquisition.

The 2025 M&A wave — real premiums paid

Why this beats the S&P 500: A 60-120% premium in 4-12 months equates to a 90-180% annualized return on the acquisition event alone. The S&P 500's best full calendar year in recent history was approximately +29%. Pre-acquisition positioning is the single most asymmetric publicly available trade — when correctly identified.

NICHE 3  Post-approval commercial ramp

Buy after FDA approval before the commercial trajectory is fully priced into analyst models

Difficulty: ●●○○○  2 / 5

The return mechanism

FDA approval is a well-known, highly anticipated event — and the market usually prices in a significant probability of approval before it happens. But for drugs in genuinely large markets with superior efficacy, the commercial ramp after approval frequently exceeds analyst consensus, creating a second re-rating opportunity distinct from the approval event itself. This niche requires reading commercial execution data, not clinical science — making it the most accessible alpha source for generalist investors.

Why analyst models are systematically conservative at launch

There are structural reasons why sell-side analysts model conservative commercial ramp assumptions for newly approved drugs. First, launch failures are common — over 50% of drugs that achieve FDA approval fail to meet their initial commercial projections. Analysts rationally apply haircuts to account for this base rate. Second, coverage of newly approved small-cap biotechs is often thin and late — many companies have only 2-3 analyst estimates at launch, and the consensus lacks the granularity of companies with 20+ analyst followers. Third, payer dynamics (formulary coverage, step therapy requirements) take 6-12 months to fully resolve, and analysts model worst-case access scenarios.

The data signals to monitor — all publicly available

• Weekly prescription data (TRx): IQVIA Symphony Health data is referenced in company earnings calls and investor presentations within 90 days of launch. A drug achieving 2x consensus TRx in its first quarter is a strong signal to increase position.

• Formulary wins: Each major payer (CVS Caremark, Express Scripts, UnitedHealth) publishes formulary decisions. A drug achieving unrestricted Tier 2 formulary access with major payers within 6 months of approval materially improves the commercial trajectory.

• Net price vs. gross price spread: The discount to list price negotiated with payers determines real revenue. Companies with strong clinical differentiation maintain narrower discounts — an indicator of commercial pricing power that consensus often underestimates.

Examples of commercial ramp exceeding consensus

• Eli Lilly, Mounjaro (2022-23): TRx data in the first two quarters of launch ran at 3-4x analyst consensus. Investors who monitored prescription data and increased their LLY position during the ramp generated superior returns versus those who waited for quarterly earnings confirmation.

• Madrigal Pharmaceuticals, Rezdiffra (2024): Reached 25,000 prescriptions in the first 90 days of launch — significantly above the 12,000-15,000 initial consensus. The stock compounded further post-approval before attracting M&A attention.

• Corcept Therapeutics, Korlym: Consistent quarterly TRx growth for six consecutive years as the drug expanded into new patient segments. Investors tracking prescription data could identify the durable ramp well before it became consensus knowledge.

Why this beats the S&P 500: This niche is the closest biotech gets to traditional growth equity investing, but with a discrete and identifiable inflection moment (FDA approval) that creates a clear entry signal. The S&P 500 offers no equivalent — there is no calendared event that triggers a similar re-rating moment for the average large-cap stock.

NICHE 4  Therapeutic area wave positioning

Own a basket in a hot area before multiple acquirers compete and escalate premiums

Difficulty: ●●○○○  2 / 5

The return mechanism

When multiple large pharmaceutical companies simultaneously identify the same therapeutic gap, they compete against each other for acquisition targets — driving premiums far above what a single-bidder situation would produce. This competitive bidding dynamic creates a premium inflation effect across an entire therapeutic area, rewarding investors who own a basket of companies in the right space before the bidding war begins. Critically, this niche requires no clinical trial expertise — only the ability to read big pharma strategic intent from public communications.

The MASH case study — competitive escalation in real time

The MASH (metabolic dysfunction-associated steatohepatitis, formerly called NASH) space in 2025 provides the definitive illustration of competitive premium escalation. Three acquisitions occurred within 150 days, each at a higher price than the last:

How to identify the next therapeutic area wave

The signals that predict a competitive bidding wave are visible in public sources 12-24 months before the first deal:

• Convergent big pharma commentary: When two or more major pharmaceutical companies name the same therapeutic area as an M&A priority in the same earnings season, competitive tension is building. Search earnings call transcripts for recurring area mentions across multiple acquirers.

• No approved therapy in a large patient population: Therapeutic areas with large unmet need and zero approved treatments attract the most aggressive competition because the market opportunity is uncapped. MASH had approximately 16 million US patients with no approved drug before Rezdiffra.

• Breakthrough Phase 2 data creating a new paradigm: A Phase 2 readout that fundamentally changes the understanding of a disease mechanism — rather than merely confirming an existing hypothesis — triggers simultaneous acquirer interest.

• 2026 candidates: Based on current big pharma commentary: CNS/neurology continued expansion (J&J, Novartis both active), cardio-metabolic (GLP-1 adjacent mechanisms), and rare genetic diseases (RNA platform targets).

Why this beats the S&P 500: You do not need to identify the exact acquisition target. Owning a basket of 5-8 companies in the right therapeutic area, when competitive bidding arrives, produces weighted average returns of 40-80% over 12-18 months. This is a sector-level trade, not a company-level trade — and it requires no scientific expertise, only strategic reading.

NICHE 5  Platform discount — venture returns in public markets

Find companies where the market prices the platform below its true sum-of-parts value

Difficulty: ●●●●●  5 / 5 

The return mechanism

Occasionally, small biotech companies trade at valuations that effectively price their lead drug at zero or even negative value — due to analyst neglect, a recent unrelated setback causing indiscriminate selling, or market scepticism about an unproven biological mechanism. In these situations, a genuinely informed investor can buy legitimate drug development platforms at valuations that would only be available to venture capital investors in private markets. The return when the market re-discovers the value can be 3-20x, independent of any acquisition or M&A activity.

Why this is the hardest niche

The critical challenge is distinguishing between a company that is cheap because the market is wrong versus a company that is cheap because the science is genuinely broken. Both look identical from the outside — low valuation, limited analyst coverage, sceptical market sentiment. The only way to reliably distinguish between them is genuine scientific literacy: the ability to read clinical data, understand biological mechanisms, and assess whether regulatory precedent exists for the approach. Most retail investors without scientific backgrounds should not attempt this niche.

The 'sum-of-parts below cash' signal

The most actionable version of this niche involves companies trading below their cash value plus any existing revenue streams — meaning the market is effectively assigning negative value to the pipeline. This occurs most frequently immediately after a disappointing clinical readout in one programme, when investors sell indiscriminately without analysing whether other pipeline assets were affected. The checklist for this signal:

• Market cap below cash + near-term revenue: If a company holds $500M in cash, generates $100M in annual licensing revenue, and trades at $450M market cap, the pipeline is being valued at -$150M. The pipeline being negative is extremely rare for a company with multiple clinical assets.

• Sell-off is programme-specific, not platform-wide: A failure in one indication does not necessarily invalidate the entire platform. RNA interference failures in oncology did not invalidate Alnylam's hepatic RNA delivery mechanism — which ultimately proved enormously successful.

• Management credibility intact: Insider buying following a selloff is a high-signal indicator. When executives purchase shares with their own money at depressed prices, they are demonstrating conviction that the setback is localised.

Historical examples of platform discounts resolving

• Alnylam Pharmaceuticals (2013-2015): RNA interference was considered a failed technology class following a wave of clinical disappointments. Alnylam's hepatic delivery mechanism was not yet recognised as fundamentally different from earlier failed approaches. Investors who understood the biological distinction and bought during the scepticism era saw 20x returns by 2021.

• Karuna Therapeutics (2019-2020): The M1/M4 muscarinic receptor mechanism for schizophrenia had been abandoned by multiple major pharma companies decades earlier. The market priced Karuna as if the mechanism was unproven — ignoring that the prior failures used pharmacologically different compounds. J&J paid $14 billion when KarXT succeeded in Phase 3.

• Arrowhead Pharmaceuticals (2018-2019): Following a clinical hold on one RNA programme, Arrowhead traded near its cash value despite a rebuilt and scientifically superior delivery platform. Investors who evaluated the rebuilt platform versus the prior version saw 8x returns before the Sarepta partnership.

Why this beats the S&P 500: A 10-20x return on a correctly identified platform discount is categorically unavailable in large-cap markets. It is effectively venture capital economics in a publicly traded vehicle — with the liquidity advantage that public markets provide and the exit optionality of either M&A or commercial launch. The price of access is genuine scientific expertise.

WHO CAN ACCESS EACH NICHE — THE HONEST HIERARCHY

Not every niche is equally accessible to every investor. The honest answer to 'which of these should I pursue?' depends almost entirely on your scientific background, the time you can dedicate to primary research, and your access to specialist information sources. The following framework maps niches to investor profiles:

The practical starting point for most retail investors

For a retail investor without a scientific background who has read this research series and wants to begin selectively investing in biotech, the recommended starting sequence is:

1. Start with Niche 4: Build a basket of 5-8 companies in one therapeutic area where you have identified converging big pharma M&A interest. This requires reading, not science. Hold the basket for 12-24 months and let competitive bidding dynamics do the work. This is the lowest-effort, highest-probability niche for a new biotech investor.

2. Add Niche 3 selectively: When a drug achieves FDA approval in a large market with differentiated efficacy, monitor the first 90-day prescription data. If TRx is running above consensus, increase your position. This is business analysis — the same skill used to evaluate any growth company.

3. Overlay Niche 2: Continuously cross-reference your holdings against the patent cliff schedules of major pharma companies. If a company you own for Niches 3 or 4 reasons also happens to fill a specific acquirer's gap, you have a natural M&A premium option built into the holding.

4. Consider Niche 1 only after 2+ years of sector experience: Catalyst event trading should not be attempted until you have sufficient sector experience to genuinely evaluate trial protocols. Many investors who lose money in biotech do so by holding through Phase 3 readouts they have not analytically evaluated.

5. Do not attempt Niche 5 without specialist expertise: Platform discount investing requires scientific depth that is genuinely rare. If you are not able to explain why a specific biological mechanism failed in previous compounds but would succeed in the current one, you are not equipped to distinguish cheap-because-wrong from cheap-because-overlooked.

FREE PRIMARY RESEARCH TOOLS EVERY BIOTECH INVESTOR SHOULD USE

One of the persistent misconceptions about biotech investing is that generating analytical edge requires expensive data subscriptions or institutional research access. In reality, the most important primary sources are entirely free and available to any investor. The following tools form the core of a retail biotech investor's research infrastructure:

Clinical and regulatory sources

• ClinicalTrials.gov: The US government registry of all clinical trials. Provides full trial protocols, primary and secondary endpoints, patient inclusion/exclusion criteria, enrolment targets, and completion timelines for every registered trial. Essential for Niche 1 (protocol reading) and Niche 4 (identifying therapeutic area activity). Free.

• FDA.gov — PDUFA dates and adcom schedules: The FDA publishes all PDUFA action dates (the target date by which the FDA must act on a drug application) and advisory committee meeting schedules. Knowing when FDA decisions are expected for companies in your portfolio enables intelligent event planning and position sizing. Free.

• FDA Complete Response Letters and approval packages: When the FDA approves a drug, it publishes the full clinical review — including the data package, labelling language, and any post-marketing commitments. These documents often contain information not available elsewhere about a drug's commercial potential. Free via FDA.gov/drugs.

Financial and corporate sources

• SEC EDGAR: Every 10-Q (quarterly report), 10-K (annual report), 8-K (material event), and Form 4 (insider buying/selling) filing is freely available. The 10-Q cash position and share count sections are non-negotiable reading before any biotech investment. Insider Form 4 filings, filed within 2 business days of any transaction, are the most reliable free signal of management conviction.

• Big pharma earnings call transcripts: Transcripts of earnings calls for J&J, Merck, AZN, AbbVie, Lilly, Pfizer, Novartis, Roche, and GSK are available free via Seeking Alpha, The Motley Fool, and company investor relations pages. Reading these calls for explicit M&A priority statements is the core research activity for Niche 2 and 4.

• JP Morgan Healthcare Conference presentations: Held each January in San Francisco, this is the most important annual gathering of pharmaceutical executives. Company presentations — including pipeline updates, commercial guidance, and strategic priorities — are available free on company investor relations pages within days of the conference.

Prescription and commercial data

• IQVIA references in earnings calls: Companies reference IQVIA Symphony Health prescription data in earnings calls and investor presentations. Comparing management's TRx commentary against analyst consensus (available in earnings preview notes) identifies whether the commercial ramp is tracking above or below expectations.

• Medical conference abstracts: ASCO (oncology), ADA (diabetes/metabolic), ASH (haematology), EASL (liver disease), and ESMO (European oncology) are the major annual medical conferences where clinical data is presented. Abstracts are published free 2-3 weeks before each conference — often the first public release of data that moves stocks significantly.

PORTFOLIO CONSTRUCTION FOR SELECTIVE BIOTECH INVESTING

The niches described in this report generate asymmetric returns only when paired with disciplined portfolio construction. The most common reason retail investors fail in biotech is not that they misidentify good drugs — it is that they size positions incorrectly relative to the binary event risk inherent in each niche.

The core sizing framework

The total portfolio context

Selective biotech investing should be positioned as a satellite allocation within a broader diversified portfolio — not as a replacement for passive index exposure. The recommended framework:

• Core holding (60-70% of portfolio): Low-cost S&P 500 or total market index fund (SPY, VOO, VTI). This is the engine of long-run compounding that biotech satellite positions cannot reliably replicate at the portfolio level.

• Selective biotech allocation (10-20% of portfolio): Individual positions across niches 2, 3, and 4 (and niche 1 and 5 for qualified investors). This is where the asymmetric biotech alpha is targeted — not through ETFs, but through informed stock selection.

• Remaining allocation (10-20%): Other sector tilts, international exposure, fixed income, or cash — per individual circumstances and risk tolerance.

The architecture of this portfolio is explicit about what each component is doing. The S&P 500 core provides reliable long-run compounding. The selective biotech allocation provides asymmetric event-driven return opportunities unavailable in passive investing. Combining both is more powerful than choosing one — because they are driven by fundamentally different return mechanisms that do not cancel each other out.

CONCLUSION

The observation that biotech ETFs have underperformed the S&P 500 over 5 and 10 years is correct and important. It is not, however, evidence that biotech investing is inferior to passive index investing. It is evidence that the ETF vehicle is structurally unable to capture the specific, event-driven returns that make biotech attractive to selective investors in the first place.

The five niches analysed in this report each represent a category of return that is structurally unavailable in the S&P 500: single-day 50-150% catalyst returns from correctly anticipated clinical trials; 60-120% acquisition premiums from pre-positioned M&A targets; 40-80% basket returns from therapeutic area competitive bidding waves; post-approval commercial ramp alpha from being early on prescription trajectory; and 3-20x platform returns from correctly identified valuation discounts. None of these return profiles exist in passive large-cap equity markets.

The price of access to these returns is selectivity — which requires time, research, and in some cases genuine scientific expertise. For investors unwilling or unable to invest the required research effort, the honest conclusion of this report series is that a low-cost S&P 500 index fund is the superior vehicle. For investors who are willing to develop the analytical framework described here, selective biotech investing offers a genuinely distinctive return profile that complements — rather than competes with — passive index exposure.

The investors who consistently outperform in biotech are not those with the best drug instincts. They are those who have the discipline to invest only when they have a specific, articulable edge; the position sizing discipline to survive being wrong; and the patience to hold through the volatility between their entry point and the event that proves them right.

If you found this analysis useful, RichStorm publishes independent pharma investment research grounded in science. Subscribe free to receive new insights directly in your inbox. [Subscribe here]

Prepared by RichStorm LLC | May 2026 | For informational purposes only. Not investment advice. All information based on publicly available sources. Past performance is not indicative of future results. Readers should consult a qualified financial adviser before making investment decisions.